Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection

NCT ID: NCT01042717

Last Updated: 2011-09-27

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-02-28
• Study Completion Date: 2011-12-31

Brief Summary

The purpose of this study is to determine whether it is safe and effective to collect peripheral blood hematopoietic stem cells 16 hours rather than the usual 11 hours after administration of plerixafor.

Detailed Description

The current FDA-approved timing for plerixafor is approximately 11 hours prior to apheresis. This is a logistical problem, since plerixafor should be administered by a health care provider, given the risk of hypotension with administration. The primary purpose of this study is, in autologous donors with non-Hodgkins lymphoma and multiple myeloma undergoing hematopoietic progenitor cell mobilization with plerixafor and G-CSF, to determine whether the dosing interval can be increased to 16 hours prior to apheresis. Patients will be admitted to a special clinical research center on the 4th day of G-CSF administration, where the peripheral blood CD34+ count will be measured every 2 hours after plerixafor administration at 5 pm until 9 AM the following day, at which time apheresis will commence. The hypothesis is that plerixafor administration 16 hours prior to apheresis is as safe and effective as plerixafor administration at 11 hours prior to apheresis.

Conditions

Multiple Myeloma; Non-Hodgkins Lymphoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Plerixafor

Plerixafor 16 hours

Group Type: EXPERIMENTAL

Plerixafor

Intervention Type: DRUG

Plerixafor administered at 16 hours prior to apheresis

Interventions

Plerixafor

Plerixafor administered at 16 hours prior to apheresis

Intervention Type: DRUG

Other Intervention Names

Mozobil

Eligibility Criteria

Inclusion Criteria

1. Autologous donors age 18 to 75 years with NHL or MM scheduled to undergo peripheral blood stem cell collection as part of standard clinical care. Biopsy-confirmed diagnosis of NHL or MM is to have been done prior to the first mobilization.

2. In first or second CR or PR

3. ECOG performance status of 0 or 1

4. WBC count greater than 2.5 x 10e9/1

5. Absolute PMN count greater than 1.5 x 10e9/1

6. PLT count greater than 100 x 10e9/1

7. Serum creatinine less than or equal to 2.2 mg/dl

8. SGOT, SGPT, and total bilirubin less than 2.5 X upper limit of normal (ULN)

9. Cardiac and pulmonary status sufficient to undergo apheresis and transplantation

10. Negative for HIV

11. 4 weeks since last cycle of chemotherapy. (Rituximab, thalidomide, dexamethasone, and bortezomib are not considered chemotherapy for the purpose of the study)

12. Patients of childbearing potential agree to use an approved form of contraception

13. Recovered from all acute toxic effects of prior chemotherapy

Exclusion Criteria

1. Comorbid condition which renders patient, in view of the investigators, at high risk of treatment complications

2. Failed previous stem cell collections or collection attempts

3. Less than 6 weeks of carmustine prior to the 1st dose of G-CSF

4. Received GM-CSF or pegfilgrastim within 3 weeks prior to the 1st dose of G-CSF for mobilization

5. Received G-CSF within 14 days prior to the 1st dose of G-CSF for mobilization

6. Active CNS involvement

7. Active brain metastases or carcinomatous meningitis

8. Bone marrow involvement greater than 20 percent

9. Received radiation therapy to the pelvis

10. Post-transplant chemotherapy and/or radiation therapy below the diaphragm is anticipated

11. Received prior radio-immunotherapy with Zevalin or Bexxar

12. Fever (temperature greater than 38 C/100.4 F)

13. Received bone-seeking radionuclides (e.g., holmium)

14. A residual acute medical condition resulting from prior chemotherapy

15. Active brain metastases or myelomatous meningitis

16. Received thalidomide, dexamethasone and/or Velcade within 7 days prior to the first dose of G-CSF

17. Received Revlimid within 3 weeks prior to the first dose of G-CSF

18. Received greater than 6 cycles of Revlimid

19. Positive pregnancy test or lactating

20. Active infection requiring antibiotic treatment

21. Abnormal ECG with clinically significant rhythm disturbance (ventricular arrhythmias), or other conduction abnormality in the last year that in the opinion of the investigator warrants exclusion of the subject from the trial.

22. Patients who previously received experimental therapy within 4 weeks of enrolling in this protocol or who are currently enrolled in another experimental protocol during the mobilization phase.

23. Patients whose apheresis product will be further selected and purified.

24. Prior autologous or allogeneic transplant.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Genzyme, a Sanofi Company

INDUSTRY

Sponsor Role: collaborator

Shi, Patricia, M.D.

INDIV

Sponsor Role: lead

Responsible Party

Patricia Shi

Assistant Professor, Hematology-Oncology

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Patricia A Shi, MD

Role: PRINCIPAL_INVESTIGATOR

Icahn School of Medicine at Mount Sinai

Locations

Mount Sinai School of Medicine

New York, New York, United States

Site Status: RECRUITING

Countries

United States

Facility Contacts

Patricia A Shi, MD

Role: primary

patricia.shi@mssm.edu

212-241-9237

Luis M Isola, MD

Role: backup

luis.isola@msnyuhealth.org

212-241-6021

References

Liles WC, Rodger E, Broxmeyer HE, Dehner C, Badel K, Calandra G, Christensen J, Wood B, Price TH, Dale DC. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion. 2005 Mar;45(3):295-300. doi: 10.1111/j.1537-2995.2005.04222.x.

Reference Type: BACKGROUND

PMID: 15752146 (View on PubMed)

DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, Nademanee A, McCarty J, Bridger G, Calandra G; 3101 Investigators. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol. 2009 Oct 1;27(28):4767-73. doi: 10.1200/JCO.2008.20.7209. Epub 2009 Aug 31.

Reference Type: BACKGROUND

PMID: 19720922 (View on PubMed)

Related Links

http://www.nlm.nih.gov/medlineplus/druginfo/meds/a609018.html

Related Info

Other Identifiers

GCO # 09-0824

Identifier Type: -

Identifier Source: org_study_id